XML 38 R13.htm IDEA: XBRL DOCUMENT v3.25.4
ADDITIONAL BALANCE SHEET DETAIL
 12 Months Ended
Dec. 31, 2025
Payables and Accruals [Abstract]  
ADDITIONAL BALANCE SHEET DETAIL ADDITIONAL BALANCE SHEET DETAIL
Prepaid expenses and other current assets are as follows (in thousands):
December 31,
Description20252024
Prepaid manufacturing— 4,029 
Restricted cash1,699 — 
Other3,771 7,321 
Total prepaid expenses and other current assets5,470 11,350 
Prepaid manufacturing expenses include advance payments to contract manufacturing organizations, or CMOs, for APIs or drug substance. Such amounts are reclassified to work-in-process inventory upon the quality release of the batches and transfer of title to the Company from the CMO.
Other prepaid expenses and other current assets, among other things, include capitalized implementation costs, prepaid insurance and prepaid information technology costs.
Other long-term assets are as follows (in thousands):
December 31,
Description20252024
Long-term inventories
$59,129 $34,953 
Restricted cash
— 1,680 
Other
552 744 
Total other long-term assets
$59,681 $37,377 
See Note 4, Inventories, for further information on long-term inventories.
Accrued expenses and other current liabilities are as follows (in thousands):
December 31,
Description20252024
Product revenue allowances$7,916 $9,657 
Product rebates64,674 6,070 
Product return provisions, current portion2,375 5,295 
Compensation and related benefits11,018 9,194 
Operating lease liabilities, current portion3,548 5,400 
Royalties due to Panion & BF Biotech, Inc.3,924 3,543 
Liability related to sale of future royalties, current portion1,664 2,039 
Professional fees1,597 1,452 
Accrued manufacturing costs1,808 1,468 
BioVectra, Inc. termination fees, current portion— 7,204 
Settlement royalties liability, current portion12,516 5,924 
Clinical trial costs1,188 1,885 
Restructuring costs, current portion— 489 
Payments due to Q325,000 — 
Other4,488 3,840 
Total accrued expenses and other current liabilities$121,716 $63,460